Telomere dysfunction resulting from telomere shortening and deregulation of shelterin components has been linked to the pathogenesis of age-related disorders, including cancer. Recent evidence suggests that BRCA1/2 (BRCA1 and BRCA2) tumor suppressor gene products play an important role in telomere maintenance. Although telomere shortening has been reported in BRCA1/2 carriers, the direct effects of BRCA1/2 haploinsufficiency on telomere maintenance and predisposition to cancer development are not completely understood. In this study, we assessed the telomere-associated and telomere-proximal gene expression profiles in peripheral blood leukocytes from patients with a BRCA1 or BRCA2 mutation, compared to samples from sporadic and familial breast cancer individuals. We found that 25 genes, including TINF2 gene (a negative regulator of telomere length), were significantly differentially expressed in BRCA1 carriers. Leukocyte telomere length analysis revealed that BRCA1/2 carriers had relatively shorter telomeres than healthy controls. Further, affected BRCA1/2 carriers were well differentiated from unaffected BRCA1/2 carriers by the expression of telomere-proximal genes. Our results link BRCA1/2 haploinsufficiency to changes in telomere length, telomere-associated as well as telomere-proximal gene expression.
vitro. 5 Other work suggests that this genomic instability may be due to deregulation of genes involved in the G 2 /M cell cycle transition and DNA damage response in BRCA1 heterozygous mutant cells, while BRCA2 heterozygous mutant cells show deregulation of genes involved in the G 1 /S cell cycle checkpoint. [6] [7] [8] Interestingly, BRCA1, but not BRCA2, heterozygous epithelial cultured cells show upregulation of the secretoglobin family of genes and expression profiles similar to those seen in stem and progenitor cells. 1 This finding corroborates a study suggesting a role for BRCA1 in regulating stemness and differentiation in breast progenitor cells. 9 A separate study demonstrated increased proliferation and clonogenic capacity, coupled with epidermal growth factor receptor (EGFR) activation, in primary mammary epithelial cells from BRCA1 mutation carriers. 10 Telomere dysfunction has been hypothesized to account for the unstable phenotype in cells derived from heterozygous BRCA1/2 mutation carriers. 4, [11] [12] [13] [14] Telomere dysfunction including telomere shortening has been linked to a variety of human age-related ailments, including cardiovascular disease, neurodegenerative disease, chronic inflammatory disease, and cancer. 15 An analysis of case control studies revealed an association between short telomeres in peripheral blood leukocytes (PBL) and elevated risk for cancers, including bladder, head and neck, lung, and kidney cancers. [16] [17] [18] [19] [20] [21] [22] Genetic anticipation, or earlier age of onset and sometimes severity of disease in successive generations, has been attributed to telomere shortening in familial cancer syndromes such as Li-Fraumeni and dyskeratosis congenita. 23 , 24 An association has been reported between genetic anticipation and shortened telomeres in hereditary breast cancers with BRCA1/2 mutations, but not in sporadic breast cancers. 14 A similar study of ovarian cancer found significantly shorter PBL telomeres in both sporadic and hereditary cases compared to healthy controls by the same group. 25 Such studies are largely association-based, and the factors driving telomere shortening and their contributions to disease development remain largely unknown. Therefore, efforts to shed light on the mechanisms driving telomere dysfunction in cancer, though limited, have offered helpful clues.
To understand the predisposition of BRCA1/2 carriers to cancer development, this pilot study focused on identifying genes that contribute to telomere dysfunction in hereditary cancer with BRCA1/2 mutations by comparing to other breast cancers (ie, familial and sporadic cancers). In addition, we determined the association between leukocyte telomere length and expression of telomere-proximal genes in BRCA1/2 mutation carriers. This study sheds light on the distinct role between BRCA1 and BRCA2 in telomere maintenance, as well as, provides insight into further investigations on the role of BRCA1/2 haploinsufficiency in the biology underlying telomere dysfunction in cancer development.
| MATERIALS AND METHODS

| Sample collection
All BRCA1/2, sporadic, and familial blood samples were obtained from Indiana University Simon Cancer Center (IUSCC), along with the approved Institutional Review Board (IRB) protocol (IRB #1011003798); 10 mL of peripheral blood was collected from total 40 women (BRCA1, n = 10; BRCA2, n = 10; hereditary breast cancer without BRCA1/2, n = 9; and sporadic breast cancer, n = 11). Five BRCA1 and 4 BRCA2 samples were from women who had not developed cancer. We also obtained freeze-dried PBL DNA of 10 healthy women (25 < age <70, median age = 49) from the Komen Tissue Bank at the IUSCC, along with IRB approval (IRB # 1206009001).
| Gene array analysis
The high-quality total RNA from blood samples was purified using 
| Quantitative reverse transcription PCR (qRT-PCR)
mRNA was extracted using the TRIzol reagent (Thermo Fisher Scientific, #15596026). cDNA was synthesized using High Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific, #4368814). qPCR was performed with SYBR Select Master mix (Thermo Fisher Scientific, #4472908) on a QuantStudio 6 Flex real-time PCR system (Applied Biosystems, Foster City, CA). Each sample was tested in triplicate in three independent experiments. Relative mRNA level was analyzed by the comparative Ct method using ACTB as a reference gene and cDNA generated from blood of healthy woman as the reference cDNA. All primers sequences were shown in Supplement Table S4 . Through the PCR analysis, P-values <0.05 were considered significant.
| Statistical analysis
Unsupervised hierarchical clustering was used to construct heat maps by the Indiana University Bioinformatics Core. Figure 1A ). Based on P-value between groups, we found a total of 46 differentially expressed genes in BRCA1 carriers compared with all other individuals (ie, BRCA2
carriers, familial, and sporadic individuals) (Supplemental Table S2 ).
One of two downregulated genes, IGFBP2 gene encodes a protein of insulin-like growth factor binding protein 2. BRCA1 has been
shown to directly interact with the insulin-like growth factor signaling and the IGFBP2 gene has been reported as a potential disease modifier in BRCA2 carriers. 31 The other downregulated gene, SERPINE1 gene's product interacts with p53 and is also likely involved in the urokinase-type plasminogen-mediated signaling pathway in breast cancer. 32, 33 Based on P-values, the top three hits were the PPP2R5C, MX1, and TINF2 genes. The PPP2R5C gene product belongs to the phosphatase 2A (PP2A) regulatory subunit B family (1.43-fold change) and has the capability to interact with BRCA1. 34 The MX1 gene encodes for interferon-induced GTPbinding protein and was previously reported as a potential downstream gene regulated by BRCA1 (1.40-fold change). 35 Notably, the TINF2 gene, which encodes for a component of the shelterin protein complex TIN2, was upregulated with a fold change of 1.54.
We next compared the above 46 genes by the resulting differential gene list from the comparison between BRCA1/2 carriers versus non-BRCA1/2 carriers, 25 out of the 46 differentially regulated genes were noted to be specifically associated with the BRCA1 carriers ( Figure 1B and Table 1 ). According to DAVID 6.8, the top three deregulated functional annotation charts were: (i) telomere/chromosome maintenance; (ii) cell cycle; and (iii) DNA binding (Supplemental Figure S1 ). qRT-PCR confirmed that the genes with the highest fold changes (TINF2, MX1, and PPP2CB) and plasminogen activator inhibitor-encoding gene (SERPINE1) were differentially expressed between BRCA1 and BRCA2 individuals ( Figure 1C Table S3 ).
| Telomere length was shorter in BRCA1/2 carriers
Because the microarray analysis revealed differential expression of negative regulators of telomere length (TINF2, TERF1, and TRER2), between BRCA1 and BRCA2 carriers, we hypothesized that the altered expression of these genes would affect telomere length among those individuals. The telomere qPCR results did not indicate significant differences in leukocyte telomere length between BRCA1 and BRCA2 carriers (Figure 2A , P = 0.24); instead, we observed that both two carriers had relatively shorter telomeres compared to healthy controls ( Figure 2B , Tumors with BRCA1 mutations are generally negative for both estrogen and progesterone receptors, whereas most tumors with BRCA2 mutations are positive for these hormone receptors. These differences may facilitate our understanding of how BRCA1 and BRCA2 mutations induce separate molecular pathways through telomere shortening (or loss) and contribute to breast cancer development.
Our findings support a previous report 14 that BRCA1/2 germline mutation carriers results in shorter overall telomere length in PBL at baseline ( Figure 2B , P = 8.0 × 10
−5
). In addition, Sedic et al reported that human mammary epithelial cells (HMECs) from BRCA1-mutation carriers (BRCA1mut/+) exhibited increased genomic instability and rapid telomere erosion. 45 However, other previous studies reported longer telomeres in PBL from BRCA1/2 carriers, or no association was found. 46, 47 These distinct conclusions are suspected to be due, in part, to the different analysis procedures. For example, Cawthon originally reported that telomere qPCR was analyzed by the standard curve method, 30 while most epidemiological telomere studies use the comparative C t method. Moreover, each study uses a different control DNA, and the detailed information was often not described well in each report.
We also compared telomere length in unaffected BRCA1/2 carriers with affected BRCA1/2 carriers and found a trend that affected BRCA carriers had shorter telomeres than unaffected BRCA1/2 carriers ( Figure 2B , P = 0.062). Although the P-value was not significant due to the small sample size, this trend may explain that hematopoietic stem-like cells suffer telomere damage in the course of disease development as well as during therapy. In addition, leukocyte telomere homeostasis could be influenced by additional environmental factors (eg, immunologic response to cancer) during carcinogenesis. In this case, leukocyte telomere length may remain short, even among BRCA1/2 patients in clinical remission. To rule out the possibility of technical bias against the qPCR-based results, we carried out classical southern bot analysis using the same DNA samples ( Figure 2C ). The results from the southern blot analysis were highly correlated with the results from telomere length qPCR (P = 0.022), indicating that the variation between two different methods was relatively small and there was no technical bias in this study ( Figure 2D ).
3.3 | Genes within one megabase of the telomere were expressed differently between affected and unaffected BRCA1/2 carriers Next, we determined whether expression of subtelomeric genes was associated with telomere shortening. To do this, we compared our microarray data with the GSE6799 dataset. 26 The dataset contains 1323 subtelomeric (within 1 Mb from telomere) genes representing all telomere ends, along with 92 random control genes, 12 housekeeping genes, and 198 other telomere-associated genes. Using this dataset, it has been reported that expression of three genes, ISG15, DSP, and C1S, located at three different subtelomeric ends (chromosome 1p, 6p, and 12p, respectively)
were increased in fibroblasts and myoblasts with telomere shortening. 26, 48 In general, we found that clusters of upregulated genes were more evident in BRCA1/2 carriers as compared to sporadic or familial individuals (Supplemental Figure S2) . When we compared genes in the GSE6799 dataset with BRCA1 individuals who had developed breast cancer versus those who had not, twenty genes were deregulated in affected BRCA1 carriers (n = 5) compared to unaffected BRCA1 carriers (n = 5). Almost all of them (19 out of 20 genes) were downregulated and only SERPINE1 gene expressed highly in affected BRCA1 carriers (Table 2) . A recent study indeed reported a role of SERPINE gene product in longevity.
The study demonstrated that carriers of the null SERPINE1 allele had a longer life span along with longer leukocyte telomere length. 49 Out of the 20 genes, 12 genes were localized within 1 Mb of the telomere (blue arrowhead with asterisk in Figure 3A ). Both Figure 3A) . We confirmed by qRT-PCR that the genes assayed have significantly altered expression levels between the affected and the unaffected BRCA2 groups ( Figure 3C ). These findings suggest that altered expression of telomere-proximal genes may be associated with the differences in telomere length among affected and unaffected BRCA1/2 carriers. Although the detailed mechanism of gene downregulation at subtelomeres due to telomere shortening remains unknown, a recent report has shown that telomeric repeat-containing RNA (TERRA) are accumulated when telomeres are critically shortened. 51 Hence, we speculate that one possible mechanism of the gene downregulation might be involved in TERRA expression levels. When TERRA expression increases and is 
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